Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4A | P27815 | 1/20 | 0.52 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.52 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.52 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.52 |
| ▸ | EGFR | P00533 | 2/20 | 0.45 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.39 |
| ▸ | AXL | P30530 | 1/20 | 0.39 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.39 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.39 |
| ▸ | MAPT | P10636 | 5/20 | 0.39 |
| ▸ | LMNA | P02545 | 5/20 | 0.39 |
| ▸ | HSP90AA1 | P07900 | 4/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.39 |
| ▸ | CCR1 | P32246 | 2/20 | 0.39 |
| ▸ | CCR8 | P51685 | 2/20 | 0.39 |
| ▸ | TP53 | P04637 | 2/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.39 |
| ▸ | MMP9 | P14780 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30831917 | 1.00 | PDE4A (0.52) | PDE4APDE4BPDE4CPDE4DEGFR | |
| SCHEMBL12560186 | 0.74 | EGFR (0.49) | EGFRKDM4EMAPTLMNAHSP90AA1 | |
| SCHEMBL13454691 | 0.74 | HSP90AA1 (0.45) | EGFRKDM4EMAPTLMNAHSP90AA1 | |
| SCHEMBL30946645 | 0.74 | EGFR (0.45) | EGFRKDM4EMAPTLMNAHSP90AA1 | |
| SCHEMBL3014296 | 0.74 | PI4KA (0.52) | EGFR | |
| SCHEMBL3237268 | 0.74 | EGFR (0.45) | EGFRKDM4EMAPTLMNAHSP90AA1 | |
| SCHEMBL29907250 | 0.72 | LMNA (0.43) | KDM4EMAPTLMNAHSP90AA1TDP1 | |
| SCHEMBL1992034 | 0.72 | LMNA (0.43) | KDM4EMAPTLMNAHSP90AA1TDP1 | |
| Hydrochloric Acid SCHEMBL30575851 | 0.72 | PI4KA (0.50) | EGFRMAPTALDH1A1MEN1KMT2A | |
| SCHEMBL8585181 | 0.72 | MAPT (0.46) | EGFRKDM4EMAPTLMNAHSP90AA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 206 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3743068-B1 | COMPOUNDS FOR THE TREATMENT OF KINASE-DEPENDENT DISORDERS | EXELIXIS INC (US) | 2026-04-29 | — | — | EP | disclosed |
| EP-4045037-B1 | HETEROARYL-BIPHENYL AMINES FOR THE TREATMENT OF PD-L1 DISEASES | CHEMOCENTRYX INC (US) | 2026-01-28 | — | — | EP | disclosed |
| US-12534450-B2 | Methods and compositions for targeting PD-L1 | ALIGOS THERAPEUTICS, INC. (US) | 2026-01-27 | — | — | US | disclosed |
| US-12522595-B2 | Bicyclic ether O-glycoprotein-2-acetamido-2-deoxy-3-D-glucopyranosidase inhibitors | BIOGEN MA INC. (US) | 2026-01-13 | — | — | US | disclosed |
| US-20250346598-A1 | HETEROARYL-BIPHENYL AMINES FOR THE TREATMENT OF PD-L1 DISEASES | CHEMOCENTRYX, INC. (US) | 2025-11-13 | — | — | US | disclosed |
| US-12390463-B2 | Dosage forms and regimens for amino acid compounds | PLIANT THERAPEUTICS, INC. (US) | 2025-08-19 | — | — | US | disclosed |
| US-12371433-B2 | Heteroaryl-biphenyl amines for the treatment of PD-L1 diseases | AMGEN INC. (US) | 2025-07-29 | — | — | US | disclosed |
| US-20250223288-A1 | AMINO ACID COMPOUNDS AND METHODS OF USE | PLIANT THERAPEUTICS, INC. | 2025-07-10 | — | — | US | disclosed |
| US-20250129098-A1 | BICYCLIC HETEROARYLAMINOALKYL PHENYL DERIVATIVES AS PI3K INHIBITORS | INCYTE HOLDINGS CORPORATION | 2025-04-24 | — | — | US | disclosed |
| EP-4520329-A2 | TREATMENT OF RESPIRATORY DISEASES WITH AMINO ACID COMPOUNDS | Pliant Therapeutics, Inc. (US) | 2025-03-12 | — | — | EP | disclosed |
| US-20030186987-A1 | Bicyclic compounds capable of inhibiting tyrosine kinases of the epidermal growth factor receptor family | BRIDGES ALEXANDER JAMES (US) | 2003-10-02 | — | — | US | disclosed |
| US-6521620-B1 | Suppressing tumors, especially breast cancers; antiproli-ferative agents; arthritis, vascular restenosis, psoriasis and angiogenesis; extremely low cytotoxicity | WARNER-LAMBERT COMPANY | 2003-02-18 | — | — | US | disclosed |
| US-6455534-B2 | ANTIPROLIVERATIVE, -CARCINOGENIC AND -TUMOR AGENTS; MITOGENESIS-ACTIVATED PROTEIN KINASE INHIBITORS; NONCYTOTOXIC; BINDING WITH HIGH AFFINITY AT THE ADENOSINE TRIPHOSPHATE BINDING SITE OF THE KINASES | WARNER-LAMBERT COMPANY | 2002-09-24 | — | — | US | disclosed |
| US-20010027197-A1 | Bicyclic compounds capable of inhibiting tyrosine kinases of the epidermal growth factor receptor family | BRIDGES ALEXANDER JAMES (US) | 2001-10-04 | — | — | US | disclosed |
| US-6265410-B1 | ANTICARCINOGENIC AGENTS | WARNER-LAMBERT COMPANY | 2001-07-24 | — | — | US | disclosed |
| US-6084095-A | INCLUDING 6-AMINO-4-(3-BROMOANILINO)PYRIDO(3,2-D)PYRIMIDINE; 4-(3-BROMOANILINO)-6-METHYLAMINOPYRIDO (3,2-D)PYRIMIDINE; AND 4-(3-BROMOANILINO)-6-METHYLAMINOPYRIDO(3,2-D)PYRIMIDINE; USEFUL IN TREATING PROLIFERATIVE DISEASES SUCH AS CANCER | WARNER-LAMBERT COMPANY (US) | 2000-07-04 | — | — | US | disclosed |
| US-5654307-A | ANTICARCINOGENIC AGENTS, ANTIARTHRITIC AGENT, SKIN DISORDERS | WARNER-LAMBERT COMPANY (US) | 1997-08-05 | — | — | US | disclosed |
| EP-0742717-A1 | BICYCLIC COMPOUNDS CAPABLE OF INHIBITING TYROSINE KINASES OF THE EPIDERMAL GROWTH FACTOR RECEPTOR FAMILY | WARNER-LAMBERT COMPANY (US) | 1996-11-20 | — | — | EP | disclosed |
| WO-1995019774-A1 | BICYCLIC COMPOUNDS CAPABLE OF INHIBITING TYROSINE KINASES OF THE EPIDERMAL GROWTH FACTOR RECEPTOR FAMILY | WARNER-LAMBERT COMPANY (US) | 1995-07-27 | — | — | WO | disclosed |
| WO-1993017682-A1 | ANGIOTENSIN II RECEPTOR ANTAGONISTS | ABBOTT LABORATORIES (US) | 1993-09-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12371433-B2 | Heteroaryl-biphenyl amines for the treatment of PD-L1 diseases | CD274, PDCD1LG2, PDCD1 | PDE4A 2968/4885PDE4B 2878/4885PDE4C 3487/4885 |
| US-20010027197-A1 | Bicyclic compounds capable of inhibiting tyrosine kinases of the epidermal growth factor receptor family | EGFR, ERBB2, ERBB3 | PDE4A 4646/4885PDE4B 4568/4885PDE4C 4196/4885 |
| US-20250346598-A1 | HETEROARYL-BIPHENYL AMINES FOR THE TREATMENT OF PD-L1 DISEASES | CD274, PDCD1LG2, PDCD1 | PDE4A 2968/4885PDE4B 2878/4885PDE4C 3487/4885 |
| US-12390463-B2 | Dosage forms and regimens for amino acid compounds | ITGB6, ITGA6, ITGAV | PDE4A 3891/4885PDE4B 3849/4885PDE4C 4382/4885 |
| US-20250223288-A1 | AMINO ACID COMPOUNDS AND METHODS OF USE | ITGB6, ITGA6, ITGA5 | PDE4A 3921/4885PDE4B 3861/4885PDE4C 4299/4885 |
| US-12534450-B2 | Methods and compositions for targeting PD-L1 | CD274, PDCD1LG2, PDCD1 | PDE4A 4503/4885PDE4B 4252/4885PDE4C 4260/4885 |
| US-20250129098-A1 | BICYCLIC HETEROARYLAMINOALKYL PHENYL DERIVATIVES AS PI3K INHIBITORS | PIK3CA, PIK3CD, PIK3R1 | PDE4A 1271/4885PDE4B 1343/4885PDE4C 1507/4885 |
| US-20030186987-A1 | Bicyclic compounds capable of inhibiting tyrosine kinases of the epidermal growth factor receptor family | EGFR, ERBB2, ERBB3 | PDE4A 4369/4885PDE4B 4298/4885PDE4C 3859/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.